QIAGEN announced the appointment of Thomas Ebeling, a leading international executive with extensive experience in the healthcare, media and consumer goods industries, as a member of the Supervisory Board with immediate effect. Mr. Ebeling joins QIAGEN as part of a process launched by the S ... more
Thermo Fisher Scientific and QIAGEN N.V. Agree on Amended Terms to Acquisition Agreement
Offer price increased
Thermo Fisher Scientific Inc. and QIAGEN N.V. announced that they have entered into an amendment to their acquisition agreement under which Thermo Fisher has commenced a tender offer to acquire all of the ordinary shares of QIAGEN.
The amendment provides for an increase from the original offer price of €39.00 to a new price of €43.00 per QIAGEN share in cash, which represents a premium of approximately 35% to the closing price of QIAGEN’s ordinary shares on the Frankfurt Prime Standard on March 2, 2020, the last trading day prior to the announcement of the acquisition agreement and Thermo Fisher’s intention to commence the offer. The amendment also provides for a reduction of the minimum acceptance threshold from 75% to 66.67% of QIAGEN’s issued and outstanding ordinary share capital at the end of the acceptance period on August 10, 2020, as well as a USD 95 million expense reimbursement to Thermo Fisher if the minimum acceptance threshold is not met.
The members of QIAGEN’s Supervisory Board and Managing Board have reaffirmed their unanimous support for the offer and their unanimous recommendation that all QIAGEN shareholders accept and tender all of their QIAGEN shares in the offer prior to the end of the acceptance period, which has now been extended to August 10, 2020. Each of the members of the Supervisory Board and Managing Board has tendered or will tender all of their QIAGEN shares in the offer.
Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific, said, “Industry dynamics have changed considerably in the past few months, creating tailwinds and headwinds for our businesses. Both of our companies are playing important roles in helping customers to battle the COVID-19 pandemic. After careful consideration, we’ve decided to increase our offer for QIAGEN to reflect the fair value of the business given the current environment. We remain confident that this transaction will create shareholder value and, importantly, provide meaningful benefits to our customers and society by combining our capabilities to combat infectious diseases and other healthcare issues. We continue to look forward to completing the transaction in the first half of 2021.”
“After carefully considering the updated offer by Thermo Fisher, QIAGEN’s Supervisory Board and Managing Board both unanimously recommend that shareholders accept this offer given that it reflects the improvements in our business performance and future prospects as a result of the coronavirus pandemic,” said Thierry Bernard, chief executive officer of QIAGEN N.V. “The rationale for this strategic step is stronger than ever, especially as the value of molecular testing becomes ever more evident. This combination is designed to enable QIAGEN employees and our portfolio of Sample to Insight solutions to have an even greater impact on society while also delivering significant cash value to our shareholders. We look forward to working closely with Thermo Fisher to successfully complete the transaction.”
QIAGEN shareholders who have already effectively accepted the offer by tendering their shares are not required to take further action in order to receive the increased offer price in accordance with the terms of the offer. Thermo Fisher’s tender offer statement on Schedule TO, including the offer document that is an exhibit thereto, and QIAGEN’s solicitation/recommendation statement on Schedule 14D-9 will be amended to reflect the revised terms of the transaction. The acceptance period is now scheduled to expire at 24:00 hours (Frankfurt am Main local time) / 18:00 hours (New York local time) on August 10, 2020.
- Thermo Fisher Scientific
QIAGEN N.V. announced the acquisition of the remaining 80.1% of diagnostics instruments company NeuMoDx Molecular, Inc. for $248 million in cash. The move rounds out QIAGEN’s portfolio of automated molecular testing solutions based on the proven PCR technology. The transaction was completed ... more
QIAGEN announced that it has obtained derogation in Germany by the Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) for its newly developed QIAstat-Dx Respiratory SARS-CoV-2 Panel test to be sold as an in vitro diagnostic (“IVD”) for the detection of SARS-CoV-2. At the same time, ... more
Thermo Fisher Scientific Inc. and QIAGEN N.V. announced that their boards of directors, as well as the managing board of QIAGEN N.V., have unanimously approved Thermo Fisher’s proposal to acquire QIAGEN for €39 per share in cash. The offer price represents a premium of approximately 23% to ... more
Thermo Fisher Scientific Inc. announced that it has completed its acquisition of FEI Company, Inc. a manufacturer of high-performance electron microscopy, for $107.50 per share in cash, or a total purchase price of approximately $4.2 billion. The completion of the transaction follows the re ... more
Thermo Fisher Scientific Inc. officially opened its new global headquarters at 168 Third Avenue in Waltham, Mass. The company designed and constructed the new 286,000-square-foot facility in accordance with green building rating systems, making it eligible for LEED (Leadership in Energy & E ... more
Proven robustness and reliability across all applications ✓ Simplified analytical workflows for screening and quantitation ✓ Exceptional levels of selectivity, sensitivity, and linear dynamic range in all sample matrices more
The Thermo Scientific™ iCAP™ PRO Series ICP-OES combines powerful multi-element capability with flexibility so your lab is ready for any challenge. more
Sensitive, universal detection with a near-uniform response ✓ Measures any non-volatile and semi-volatile analytes at sub-nanogram ✓ Does not require a chromophore or ionization more
Transform everyday quantitation, screening and sample profiling through unique depth in analysis, with highest accuracy and precision. Gain the flexibility to keep pace with ever-changing regulations, explore new opportunities through increased scope and method consolidation. Simplify analy ... more
Routine laboratories analyzing for trace elements are ever more committed to reducing cost per sample by decreasing method runtimes and looking for best-in-class robustness. The Thermo Scientific™ iCAP™ PRO Series ICP-OES combines powerful multi-element capability with flexibility so your l ... more
The problem with almost every other type of detector is that there is a bias. The bias might be that one analyte responds more than another or that mobile phase affects detection differently. A charged aerosol detector measures analyte charge that is in direct proportion to the amount of th ... more
Comprehensive collection of information for clinical/translational/drug monitoring research, forensic testing, and sports antidoping analysis more
Discover instrumental solutions and workflows to meet regulatory demands and hear about latest work done in the area if emerging contaminants. more
Organizations have made significant investments in enterprise and laboratory tools, technologies and solutions to help improve productivity, better manage data/information and optimize their business processes. However, the reality is that most comp more
- 1Detect neurodegenerative diseases such as Alzheimer's by a simple eye scan?
- 2Fluorescence microscopy at highest spatial and temporal resolution
- 3The Mechanics of the Immune System
- 4Resolve Biosciences Launches New Era in Single-Cell Spatial Analysis
- 5Quick look under the skin
- 6New ion trap to create the world's most accurate mass spectrometer
- 7How does your computer smell?
- 8Clocking electron movements inside an atom
- 9Sartorius closes 2020 with strong growth
- 10A clear path to better insights into biomolecules
- QIAGEN expands Supervisory Board with appointment of a new member
- Thermo Fisher Scientific and QIAGEN N.V. Agree on Amended Terms to Acquisition Agreement
- QIAGEN launches coronavirus test kit in Germany following derogation by BfArM
- QIAGEN dramatically ramping up global production capacity for RNA extraction kits for use in detection of SARS-CoV-2 coronavirus
- Thermo Fisher Scientific to Acquire QIAGEN